Compare EPM & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EPM | NKTX |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.3M | 133.5M |
| IPO Year | 1996 | 2020 |
| Metric | EPM | NKTX |
|---|---|---|
| Price | $3.76 | $1.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $4.75 | ★ $13.25 |
| AVG Volume (30 Days) | 426.6K | ★ 623.5K |
| Earning Date | 11-11-2025 | 11-10-2025 |
| Dividend Yield | ★ 12.77% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $85,232,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.97 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.71 | $1.31 |
| 52 Week High | $5.70 | $2.74 |
| Indicator | EPM | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 32.91 | 43.79 |
| Support Level | $3.75 | $1.80 |
| Resistance Level | $4.27 | $1.90 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 2.91 | 42.50 |
Evolution Petroleum Corp is an independent energy company focused on owning and investing in onshore oil and natural gas properties across the United States. Its portfolio includes non-operated interests in various production fields such as CO2 enhanced oil recovery in Louisiana, secondary recovery production in Wyoming, and shale gas reservoirs in Texas and North Dakota. The company generates revenue from the production and sale of oil and natural gas, leveraging specialized technologies to extend reservoir life and enhance recoveries.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.